This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by AstraZeneca.
Reference
Telford C, et al. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. PharmacoEconomics-Open : 25 Apr 2019. Available from: URL: https://rd.springer.com/article/10.1007/s41669-019-0134-3
Rights and permissions
About this article
Cite this article
Fulvestrant 500mg cost effective in HR+ advanced breast cancer in UK. PharmacoEcon Outcomes News 827, 19 (2019). https://doi.org/10.1007/s40274-019-5857-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5857-y